Singapore markets closed

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
29.96-0.27 (-0.89%)
At close: 05:35PM CEST

Fresenius SE & Co. KGaA

Else-Kroener-Strasse 1
Bad Homburg vor der Höhe 61352
Germany
49 6172 6080
https://www.fresenius.com

Sector(s)Healthcare
IndustryMedical Care Facilities
Full-time employees190,863

Key executives

NameTitlePayExercisedYear born
Mr. Michael SenCEO, President & Chairman of Management Board of Fresenius Management SE4.09MN/A1968
Ms. Sara Lisa HennickenCFO & Member of the Management Board - Fresenius Management SE1.55MN/A1980
Mr. Pierluigi AntonelliMember of Management Board of Fresenius Management SE & CEO of Fresenius Kabi2MN/AN/A
Dr. Michael Sven Moser Ph.D.Member of Management Board of Fresenius Management SE1.2MN/A1978
Mr. Robert MollerMember of the Management Board of Fresenius Management SE1.15MN/A1971
Mr. Markus GeorgiSenior Vice President of Investor RelationsN/AN/AN/A
Matthias LinkSenior Vice President Corporate CommunicationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Corporate governance

Fresenius SE & Co. KGaA’s ISS governance QualityScore as of 1 July 2024 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.